FDA keeps Solid Bio's troubled Duchenne MD gene therapy on clinical lockdown in latest setback

Much-maligned Solid Biosciences received yet another spate of bad news late Friday regarding its Duchenne muscular dystrophy gene therapy program.

It’s been almost nine months since the FDA announced a second clinical hold on Solid Bio’s Phase I/II trial for an AAV-based Duchenne MD treatment. And after extending that hold in May, US regulators again decided they needed more info with another extension on Friday.